AGTC plans to advance its achromatopsia B3 candidate to the next stage of development after 12-month phase 1/2 trial data showed positive biologic activity, according to a company press release.
Achromatopsia (ACHM) candidate B3 data for 25 patients with mutations in the ACHM B3 gene showed improvements in visual sensitivity measured by static perimetry and ocular photosensitivity analyzer, the release said. In addition to the positive biologics, patient anecdotes were also positive.
The B3 trial showed improved retinal sensitivity in the treated eye compared with the untreated eye in four of